Evidence-making controversies: the case of hepatitis C treatment and the promise of viral elimination

References

• ANRS Collaborative Study Group on Hepatocellular Carcinoma. (2016). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. Journal of Hepatology,65, 734–740.
   PubMed Web of Science ®Google Scholar
• Aspinall, E. J., Corson, S., Doyle, J. S., Grebely, J., Hutchinson, S. J., Dore, G., … Hellard, M. E. (2013). Treatment of hepatitis C virus infection among people who are actively injecting drugs: A systematic review and meta-analysis. Clinical Infectious Diseases,57, S80–S89.10.1093/cid/cit306
   PubMed Web of Science ®Google Scholar
• Australian Health Organizations. (2017, June 26). Australian health organisations refute Cochrane Review Report and affirm efficacy of Direct Acting Antiviral (DAA) therapy for hepatitis C. Retrieved from http://www.hepatologyassociation.com.au/public/23/system/newsAttachments/Position%20Statement_Refuting_Cochrane_Review_on_efficacy_of_DAA_therapy%20(002).pdf
   Google Scholar
• Bacchi, C., & Goodwin, S. (2016). Poststructural Policy Analysis. London: Palgrave.
   Google Scholar
• Banerjee, D., & Reddy, K. R. (2016). Review article: Safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Alimentary Pharmacology & Therapeutics,43, 674–696.10.1111/apt.2016.43.issue-6
   PubMed Web of Science ®Google Scholar
• Bayer, R., Johns, D., & Galea, S. (2012). Salt and public health: Contested science and the challenge of evidence-based decision making. Health Affairs,31, 2738–2746.10.1377/hlthaff.2012.0554
   Web of Science ®Google Scholar
• Blumer, H. (1969). Symbolic interactionism. Englewood Cliffs, NJ: Prentice Hall.
   Google Scholar
• Brown, N., & Michael, M. (2003). A sociology of expectations: Retrospecting prospects and prospecting retrospects. Technology Analysis and Strategic Management,15, 3–18.10.1080/0953732032000046024
   Web of Science ®Google Scholar
• Clarke, A. (2015). Anticipation work: Abduction, simplification, hope. In G. C.Bowker, S.Timmermans, A.Clarke, & E.Balka (Eds.), Boundary objects and beyond (pp. 85–120). London: MIT Press.
   Google Scholar
• Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., … Brillanti, S. (2016). Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. Journal of Hepatology,65, 727–733.10.1016/j.jhep.2016.06.015
   PubMed Web of Science ®Google Scholar
• Deleuze, G., & Guattari, F. (1988). A thousand plateaus. London: Athlone Press.
   Google Scholar
• Duff, C. (2014). Assemblages of Health. London: Springer.
   Google Scholar
• EC Partnership. (2017). Retrieved from https://www.burnet.edu.au/projects/274_the_eliminate_hepatitis_c_partnership_the_ec_partnership
   Google Scholar
• European Association for the Study of the Liver. (2017, June 26). Response to the Cochrane systematic review on DAA-based treatment of chronic hepatitis C. Journal of Hepatology. doi:10.1016/j.jhep.2017.06.022
   Google Scholar
• European Liver Patients’ Association. (2017). ELPA joins hepatitis community worldwide in their unanimous response to the Cochrane systematic review on effectiveness of antiviral therapy. Retrieved from http://www.elpa.eu/news/jul-2017/response-media-coverage-cochrane-study-daa-based-treatment-chronic-hepatitis-c
   Google Scholar
• Foster, G., Irving, W., Cheung, M., Walker, A., Hudson, B., Verma, S., … HCV Research UK. (2016). Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology,64, 1224–1231.10.1016/j.jhep.2016.01.029
   PubMed Web of Science ®Google Scholar
• Gane, E. (2014). Hepatitis C beware – The end is nigh. The Lancet,384, 1557–1560.10.1016/S0140-6736(14)61225-3
   PubMed Web of Science ®Google Scholar
• Gastroenterological Society of Australia. (2017, June 16). Experts reject flawed report and reaffirm support for new generation hepatitis C therapies. Retrieved from http://www.hepatologyassociation.com.au/public/23/system/newsAttachments/GESA%20Media%20Release%20HCV%20DAAs_15%20June%202017.pdf
   Google Scholar
• Graudal, N. A., Hubeck-Graudal, T., & Jurgens, G. (2011). Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamine, cholesterol and triglyceride. Cochrane Database Systematic Review, CD004022.
   PubMed Web of Science ®Google Scholar
• Grebely, J., Matthews, G. V., Lloyd, A. R., & Dore, G. J. (2013). Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: Feasibility and future requirements. Clinical Infectious Diseases,57, 1014–1020.10.1093/cid/cit377
   PubMed Web of Science ®Google Scholar
• Green, J., & Britten, N. (1998). Qualitative research and evidence-based medicine. British Medical Journal,316, 1230–1232.10.1136/bmj.316.7139.1230
   PubMed Web of Science ®Google Scholar
• Greenhalgh, T., Snow, R., Ryan, S., Rees, S., & Salisbury, H. (2015). Six biases against patients and carers in evidence-based medicine. BMC Medicine,13, 1.
   PubMed Web of Science ®Google Scholar
• Guardian. (2017a, June 14). Hepatitis C antiviral drugs are effective. Retrieved from http://www.theguardian.com/society/2017/jun/13/hepatitis-c-antiviral-drug-are-effective
   Google Scholar
• Guardian. (2017b, June 9). Miracle hepatitis C drugs costing £30 k per patient may have no clinical effect. Retrieved from https://www.theguardian.com/society/2017/jun/08/miracle-hepatitis-c-drugs-costing-30 k-per-patient-may-have-no-clinical-effect
   Google Scholar
• Hagan, L. M., Wolpe, P. R., & Schinazi, R. F. (2013). Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends in Microbiology,21, 625–633.10.1016/j.tim.2013.09.008
   PubMed Web of Science ®Google Scholar
• He, F. J., & MacGregor, G. A. (2011). Salt reduction lowers cardiovascular risk: Meta-analysis of outcome trials. The Lancet,378, 380–382.10.1016/S0140-6736(11)61174-4
   PubMed Web of Science ®Google Scholar
• Hellard, M. (2016). Retrieved from https://www.mja.com.au/insight/016/7/exciting-times-hepatitits-c-treatment
   Google Scholar
• Hellard, M., Doyle, J. S., Sacks-Davis, R., Thompson, A. J., & McBryde, E. (2014). Eradication of hepatitis C infection: The importance of targeting people who inject drugs. Hepatology,59, 366–369.10.1002/hep.v59.2
   PubMed Web of Science ®Google Scholar
• Hepatitis C Coalition. (2017). The hepatitis C coalition’s response to the Cochrane review on hepatitis C medicines. British Medical Journal,357, j2961.
   PubMed Web of Science ®Google Scholar
• Jakobsen, J. C., Nielsen, E. F., Feinberg, J., Katakam, K. K., Fobain, K., Hauser, G., … Gluud, C. (2017). Direct-acting antivirals for chronic hepatitis. Cochrane Database of Systematic Reviews,6, CD012143. doi:10.1002/14651858.CD012143
   PubMedGoogle Scholar
• Knorr-Cetina, K. (1999). Epistemic cultures: How the sciences make knowledge. Cambridge, MA: Harvard University Press.
   Google Scholar
• Lancaster, K. (2016). Performing the evidence-based drug policy paradigm. Contemporary Drug Problems,43, 142–153.10.1177/0091450916633306
   Google Scholar
• Latour, B. (1987). Science in action. Cambridge, MA: Harvard University Press.
   Google Scholar
• Latour, B. (2004). Why has critique run out of steam? From matters of fact to matters of concern. Critical Inquiry,30, 225–248.
   Web of Science ®Google Scholar
• Law, J. (2004). After method. Oxon: Routledge.
   Google Scholar
• Law, J. (2007). Making a mess with method. In W.Outhwaite & S. P.Turner (Eds.), The SAGE handbook of social science methodology (pp. 595–606). London: Sage.10.4135/9781848607958
   Google Scholar
• Law, J., & Singleton, V. (2000). Performing technology’s stories: On social constructivism, performance, and performativity. Technology and Culture,41, 765–775.10.1353/tech.2000.0167
   Web of Science ®Google Scholar
• MacParland, S. A., Pham, T. N. Q., Guy, C. S., & Michalak, T. I. (2009). Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology,49, 1431–1441.10.1002/hep.22802
   PubMed Web of Science ®Google Scholar
• Martin, N. K., Vickerman, P., Dore, G., Grebely, J., Miners, A., Cairns, J., … Hickman, M. (2016). Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. Journal of Hepatology,65, 17–25.10.1016/j.jhep.2016.02.007
   PubMed Web of Science ®Google Scholar
• Mattingly, S. (2010). The paradox of hope. Berkeley: University of California Press.
   Google Scholar
• Mol, A. (2002). The body multiple. Durham, NC: Duke University Press.10.1215/9780822384151
   Google Scholar
• Mykhalovskiy, E., & Weir, L. (2004). The problem of evidence-based medicine: Directions for social science. Social Science & Medicine,59, 1059–1069.10.1016/j.socscimed.2003.12.002
   PubMed Web of Science ®Google Scholar
• Nault, J.-C., & Colombo, M. (2016). Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. Journal of Hepatology,65, 663–665.10.1016/j.jhep.2016.07.004
   PubMed Web of Science ®Google Scholar
• Novas, C. (2006). The political economy of hope: Patients’ organizations, science and biovalue. BioSocieties,1, 289–305.10.1017/S1745855206003024
   Google Scholar
• Pearlman, B. L., & Traub, N. (2011). Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: A cure and so much more. Clinical Infectious Diseases,52, 889–900.10.1093/cid/cir076
   PubMed Web of Science ®Google Scholar
• Reig, M., Mariño, Z., Perelló, C., Iñarrairaegui, M., Ribeiro, A., Lens, S., … Bruix, J. (2016). Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. Journal of Hepatology,65, 719–726.10.1016/j.jhep.2016.04.008
   PubMed Web of Science ®Google Scholar
• Rhodes, T. (2018). The becoming of methadone in Kenya: How an intervention’s implementation constitutes recovery potential. Social Science & Medicine,201, 71–79.
   PubMed Web of Science ®Google Scholar
• Rhodes, T., Closson, Elizabeth F., Paparini, S., Guise, A., & Strathdee, S. (2016). Towards ‘evidence-making intervention’ approaches in the social science of implementation science: The making of methadone in East Africa. International Journal of Drug Policy,30, 17–26.10.1016/j.drugpo.2016.01.002
   PubMed Web of Science ®Google Scholar
• Sackett, D. L., Rosenberg, W. M. C., Gray, J. A. M., & Haynes, R. B. (1996). Evidence based medicine: What it is and what it isn’t. British Medical Journal,312, 71.10.1136/bmj.312.7023.71
   PubMed Web of Science ®Google Scholar
• Scott, N., McBryde, E., Thompson, A. J., Doyle, J. S., & Hellard, M. (2016). Treatment scale-up to achieve global HCV incidence and mortality elimination targets: A cost-effectiveness model. Gut,1–9.
   Web of Science ®Google Scholar
• Seeff, L. B. (2013). Sustained virologic response: Is this equivalent to cure of chronic hepatitis C?Hepatology,57, 438–440.10.1002/hep.25964
   PubMed Web of Science ®Google Scholar
• Simmons, B., Saleem, J., Heath, K., Cooke, G. S., & Hill, A. (2015). Long-term treatment outcomes of patients infected with hepatitis C virus: A systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clinical Infectious Diseases,61, 730–740.10.1093/cid/civ396
   PubMed Web of Science ®Google Scholar
• Smith-Palmer, J., Cerri, K., & Valentine, W. (2015). Achieving sustained virologic response in hepatitis C: A systematic review of the clinical, economic and quality of life benefits. BMC Infectious Diseases,15, 1333. doi:10.1186/s12879-015-0748-8
   Web of Science ®Google Scholar
• Stengers, I. (2005). The cosmopolitical proposal. In B.Latour & P.Weibel (Eds.), Making things public (pp. 994–1003). Cambridge, MA: MIT Press.
   Google Scholar
• Sussman, N. L., Remien, C. H., & Kanwal, F. (2014). The end of hepatitis C. Clinical Gastroenterology and Hepatology,12, 533–536.10.1016/j.cgh.2014.01.025
   PubMed Web of Science ®Google Scholar
• van der Meer, A. J., & Berenguer, M. (2016). Reversion of disease manifestations after HCV eradication. Journal of Hepatology,65, S95–S108.10.1016/j.jhep.2016.07.039
   PubMed Web of Science ®Google Scholar
• Watson, H., Wood-Harper, T., & Wood, B. (1995). Interpreting methodology under erasure: Between theory and practice. Systems Practice,8, 441–468.10.1007/BF02253395
   Web of Science ®Google Scholar
• Whatmore, S. J. (2009). Mapping knowledge controversies: Science, democracy and the redistribution of expertise. Progress in Human Geography,33, 587–598.10.1177/0309132509339841
   Web of Science ®Google Scholar
• Wood, M., Ferlie, E., & Fitzgerald, L. (1998). Achieving clinical behaviour change: A case of becoming indeterminate. Social Science & Medicine,47, 1729–1738.10.1016/S0277-9536(98)00250-0
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2016). Global health sector strategies: Viral hepatitis, 2016–2021. Geneva: Author.
   Google Scholar
• World Hepatitis Alliance. (2017a). An open letter to the Cochrane Collaboration. Lancet Gastroenterology and Hepatology,8, 549.
   Google Scholar
• World Hepatitis Alliance. (2017b, June 13) Findings from hepatitis C study should not deter patients from seeking treatment or governments from funding it. Retrieved from http://www.worldhepatitisalliance.org/news/jun-2017/%E2%80%9Cfindings-hepatitis-c-study-should-not-deter-patients-seeking-treatment-or-governments
   Google Scholar
• Zoulim, F., Liang, T. J., Gerbes, A. L., Aghemo, A., Deuffic-Burban, S., Dusheiko, G., … Wiktor, S. (2015). Hepatitis C virus treatment in the real world: Optimising treatment and access to therapies: Table 1. Gut,64, 1824–1833.10.1136/gutjnl-2015-310421
   PubMed Web of Science ®Google Scholar
• Zournazi, M. (2002). Hope: New philosophies for change. London: Pluto Press.
   Google Scholar